Tvardi Therapeutics (TVRD) Receivables - Net (2014 - 2025)
Tvardi Therapeutics (TVRD) posted Receivables - Net of $1.2 million for Q1 2025, up 182.53% sequentially from $435000.0 in Q3 2024, and down 28.46% YoY from $1.7 million in Q1 2024.
Tvardi Therapeutics (TVRD) Receivables - Net (2014 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Receivables - Net for 5 years, with the latest figure at $1.2 million in Q1 2025.
- Quarterly Receivables - Net fell 28.46% year-over-year to $1.2 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.2 million (down 28.46% YoY) and the FY2024 annual result came in at $407000.0, down 85.28% from the prior year.
- Receivables - Net grew to $1.2 million in Q1 2025 per TVRD's latest filing, from $435000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $20.0 million in Q3 2021 and troughed at $359000.0 in Q2 2024.
- A 4-year average of $4.3 million and a median of $1.7 million in 2024 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2024 and 2025: Receivables - Net slumped 87.02% in 2024, then slipped 28.46% in 2025.
- Over 4 years, Receivables - Net stood at $20.0 million in 2021, then sank by 86.2% to $2.8 million in 2023, then tumbled by 84.27% to $435000.0 in 2024, then jumped by 182.53% to $1.2 million in 2025.
- According to Business Quant data, Receivables - Net over the past three periods registered $1.2 million, $435000.0, and $359000.0 for Q1 2025, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.23 Mn |
| Mar 31, 2025 | 1.23 Mn |
| Sep 30, 2024 | 435,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 359,000.00 |
| Jun 30, 2024 | 359,000.00 |
| Mar 31, 2024 | 1.72 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Dec 31, 2023 | 2.77 Mn |
| Dec 31, 2023 | 2.77 Mn |
| Sep 30, 2023 | 3.35 Mn |
| Sep 30, 2023 | 3.35 Mn |
| Sep 30, 2021 | 20.03 Mn |
| Sep 30, 2021 | 20.03 Mn |
| Jun 30, 2014 | 480,000.00 |
| Jun 30, 2014 | 480,000.00 |